

# ESMO-The Christie Preceptorship on Lung Cancer

## PROGRAMME

**ESMO  
PRECEPTORSHIP**

**MANCHESTER UNITED KINGDOM  
12-14 MARCH 2025**

**Co-Chairs**

Fiona Blackhall, United Kingdom  
Raffaele Califano, United Kingdom  
Pilar Garrido López, Spain

# ESMO-THE CHRISTIE PRECEPTORSHIP PROGRAMME LUNG CANCER

Multidisciplinary management, standards of care and future perspectives

**Manchester, United Kingdom**  
**12-14 March 2025**

---

## CO-CHAIRS

Fiona Blackhall, United Kingdom  
Raffaele Califano, United Kingdom  
Pilar Garrido López, Spain

## SPEAKERS

Paul Baas, Netherlands  
Haval Balata, United Kingdom  
Claire Barker, United Kingdom  
Richard Booton, United Kingdom  
Clara Chan, United Kingdom  
Christopher Craig, United Kingdom  
Simon Ekman, Sweden  
Corinne Faivre-Finn, United Kingdom  
Enriqueta Felip, Spain  
Lizza Hendriks, Netherlands  
Keith M. Kerr, United Kingdom  
Jennifer A. King, United Kingdom

Rohit Kochhar, United Kingdom  
Cécile Le Péchoux, France  
Colin Lindsay, United Kingdom  
Luis Paz-Ares, Spain  
David Planchard, France  
Martin Reck, Germany  
Christina H. Ruhlmann, Denmark  
Suresh Senan, Netherlands  
Yvonne Summers, United Kingdom  
Fiona Thistlethwaite, United Kingdom  
Paul E. Van Schil, Belgium  
Giulia Veronesi, Italy

---

## LEARNING OBJECTIVES

- To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
- To learn about the management of early-stage NSCLC and use of adjuvant treatments
- To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
- To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
- To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about treatment of NSCLC with oligometastatic disease
- To learn about the systemic treatment of mesothelioma and SCLC
- To learn about the role of supportive and palliative care for thoracic malignancies

---

## ACCREDITATION

The programme of this event has been accredited with **16 ESMO-MORA category 1 points**.  
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



## Wednesday, 12 March 2025

08:15-09:15 60'	Registration	
09:15-09:25 10'	Welcome & Introduction	Fiona Blackhall, UK Raffaele Califano, UK Pilar Garrido López, ES
09:25-12:25 180'	<b>SESSION 1</b> Screening and diagnostics for lung cancer	<b>Co-Chairs:</b> Raffaele Califano, UK Fiona Blackhall, UK
30'	Lung cancer screening	Haval Balata, UK
30'	EBUS TBNA in diagnosis/staging of lung cancer	Richard Booton, UK
10:25-10:55	<b>Coffee break</b>	
30'	Role of pathologist in diagnosis and mutation analysis of lung cancer	Keith M. Kerr, UK
30'	PET/CT in staging of lung cancer	Rohit Kochhar, UK
30'	Diagnosis and management of malignant pleural effusion	Christopher Craig, UK
12:25-13:25	<b>Lunch</b>	
13:25-16:25 180'	<b>SESSION 2</b> Radical treatment of early stage NSCLC	<b>Co-Chairs:</b> Cécile Le Péchoux, FR Giulia Veronesi, IT
30'	Surgery for early-stage NSCLC	Giulia Veronesi, IT
30'	Stereotactic ablative RT for early-stage NSCLC	Suresh Senan, NL
30'	Adjuvant radiotherapy for completely resected early-stage NSCLC	Cécile Le Péchoux, FR
14:55-15:25	<b>Coffee break</b>	
30'	Adjuvant systemic therapies for resected early-stage NSCLC	Raffaele Califano, UK
30'	Perioperative immunotherapy-based strategies for resectable NSCLC	Yvonne Summers, UK
16:25-17:25 60'	<b>SESSION 3</b> Locally advanced NSCLC	<b>Co-Chairs:</b> Clara Chan, UK Paul E. Van Schil, BE
30'	Combined modality treatment for unresectable NSCLC	Clara Chan, UK
30'	Role of surgery for N2 disease	Paul E. Van Schil, BE
17:25-17:35 10'	Close of day 1	Fiona Blackhall, UK Raffaele Califano, UK Pilar Garrido López, ES

Thursday, 13 March 2025

<b>09:00-12:00</b> <b>180'</b>	<b>SESSION 4</b> <b>Advanced NSCLC</b>	<b>Co-Chairs:</b> <b>Fiona Blackhall, UK</b> <b>Martin Reck, DE</b>
30'	First-line immune-checkpoint blockade for advanced NSCLC	Luis Paz-Ares, ES
30'	First-line chemotherapy for advanced NSCLC	David Planchard, FR
30'	Second-line treatment for advanced NSCLC	Martin Reck, DE
<b>10:30-11:00</b>	<b>Coffee break</b>	
30'	Treatment of EGFR mutant advanced NSCLC	Raffaele Califano, UK
30'	Treatment of ALK and ROS1 positive advanced NSCLC	Fiona Blackhall, UK
<b>12:00-13:00</b>	<b>Lunch</b>	
<b>13:00-14:30</b> <b>90'</b>	<b>SESSION 5</b> <b>Palliative treatment of lung cancer and mesothelioma</b>	<b>Co-Chairs:</b> <b>Pilar Garrido López, ES</b> <b>Simon Ekman, SE</b>
30'	Treatment of advanced NSCLC harboring KRAS mutation and MET aberrations	Colin Lindsay, UK
30'	Beyond EGFR, ALK, ROS1, KRAS and MET: Novel molecularly driven targeted therapies in NSCLC	Simon Ekman, SE
30'	Treatment of oligometastatic NSCLC	Lizza Hendriks, NL
<b>14:30-15:00</b>	<b>Coffee break</b>	
<b>15:00-17:30</b> <b>150'</b>	<b>SESSION 5 - cont.</b> <b>Palliative treatment of lung cancer and mesothelioma</b>	<b>Co-Chairs:</b> <b>Paul Baas, NL</b> <b>Christina H. Ruhlmann, DK</b>
30'	Systemic treatment of mesothelioma	Paul Baas, NL
30'	Radical treatment of brain metastases: The importance of a neuro-oncology multi-disciplinary approach	Jennifer A. King, UK
30'	Supportive and palliative care in lung cancer	Christina H. Ruhlmann, DK
60'	Participants clinical case discussion (6x10')	Faculty
<b>17:30-17:40</b> <b>10'</b>	<b>Close of day 2</b>	<b>Fiona Blackhall, UK</b> <b>Raffaele Califano, UK</b> <b>Pilar Garrido López, ES</b>
<b>19:00</b>	<b>Welcome drink</b>	
<b>19:30</b>	<b>Dinner</b>	

Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion

## Friday, 14 March 2025

<b>09:00-10:30</b> 90'	<b>SESSION 6</b> <b>SCLC</b>	<b>Co-Chairs:</b> <b>Corinne Faivre-Finn, UK</b> <b>Pilar Garrido López, ES</b>
30'	Second-line therapies for SCLC	Enriqueta Felip, ES
30'	First-line chemo-immunotherapy for SCLC	Pilar Garrido López, ES
30'	Treatment of limited stage SCLC	Corinne Faivre-Finn, UK
<b>10:30-11:00</b>	<b>Coffee break</b>	
<b>11:00-12:30</b> 90'	<b>SESSION 6 - cont.</b> <b>SCLC</b>	<b>Co-Chairs:</b> <b>Fiona Blackhall, UK</b> <b>Raffaele Califano, UK</b>
30'	Novel targeted therapies in SCLC	Fiona Blackhall, UK
30'	Prophylactic cranial irradiation and role of thoracic RT for extensive stage SCLC	Claire Barker, UK
30'	Next generation therapeutics for lung cancer	Fiona Thistlethwaite, UK
<b>12:30-12:35</b> 5'	<b>Conclusion and farewell</b>	<b>Fiona Blackhall, UK</b> <b>Raffaele Califano, UK</b> <b>Pilar Garrido López, ES</b>
<b>12:35-13:35</b>	<b>Lunch</b>	